Epilepsy meets cancer: When, why, and what to do about it?

The Lancet Oncology

Volumn 13, Issue 9, 2012, Pages

  Weller, Michael ^a   Stupp, Roger ^b   Wick, Wolfgang ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTACID AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CYTARABINE; CYTOCHROME P450; DOXORUBICIN; EPOXIDE HYDROLASE; ETIRACETAM; GABAPENTIN; HARKOSERIDE; HISTONE DEACETYLASE; LAMOTRIGINE; METHYLTRANSFERASE INHIBITOR; MORPHINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RIFAMPICIN; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; VINCRISTINE; ZONISAMIDE;

ALLERGY; ANAMNESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ATAXIA; BLOOD BRAIN BARRIER; BLOOD CLOTTING DISORDER; BRAIN METASTASIS; BRAIN TUMOR; CANCER DIAGNOSIS; CEREBELLUM ATROPHY; COGNITION; COGNITIVE DEFECT; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; EPILEPSY; FATIGUE; GENERALIZED EPILEPSY; GINGIVA HYPERPLASIA; HEADACHE; HUMAN; HYPONATREMIA; INFECTION; LEUKOPENIA; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; NAUSEA; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SKIN TOXICITY; STROKE; TERATOGENICITY; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; TREMOR; VISUAL FIELD DEFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CAUSALITY; COMORBIDITY; DRUG INTERACTIONS; HUMANS; MENINGEAL CARCINOMATOSIS; PHENOBARBITAL; PHENYTOIN; RADIOTHERAPY; SEIZURES;

EID: 84865568082     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70266-8     Document Type: Review

References (61)

1. Van Breemen MS, Wilms EB, Vecht CJ Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007, 6:421-430.
2. De Groot M, Reijneveld JC, Aronica E, Heimans JJ Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment. Brain 2012, 135:1002-1016.
3. Patsalos PN, Perucca E Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003, 2:473-481.
4. Yap KY, Chui WK, Chan A Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 2008, 30:1385-1407.
5. Kwan P, Schachter SC, Brodie MJ Drug-resistant epilepsy. N Engl J Med 2011, 365:919-926.
6. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010, 51:676-685.
7. Singh G, Hernaiz Driever P, Sander JW Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 2005, 128:7-17.
8. Singh G, Bell GS, Hernaiz-Driever P, Sander JW Cancer risk in people with epilepsy using valproate-sodium. Acta Neurol Scand 2012, 125:234-240.
9. Singh G, Rees JH, Sander JW Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. J Neurol Neurosurg Psychiatry 2007, 78:342-349.
10. Wick W, Menn O, Meisner C, et al. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long?. Onkologie 2005, 28:391-396.
11. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51:1069-1077.
12. Klein M, Engelberts NH, van der Ploeg HM, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 2003, 43:514-520.
13. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54:1886-1893.
14. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1000-1015.
15. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1016-1026.
16. Van Breemen MSM, Rijsmann RM, Taphoorn MJB, Walchenbach R, Zwinkels H, Vecht CJ Efficacy of antiepileptic drugs in patients with gliomas and seizures. J Neurol 2009, 256:1519-1526.
17. Rosati A, Buttolo L, Stefini R, Todeschini A, Cenzato M, Padovani A Efficacy and safety of levetiracetam in patients with glioma. A clinical prospective study. Arch Neurol 2010, 67:336-343.
18. Bähr O, Hermisson M, Rona S, et al. Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. Acta Neurochir 2012, 154:229-235.
19. Maschio M, Dinapoli L, Mingoia M, et al. Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. J Neurol 2011, 258:2100-2104.
20. De Groot M, Aronica E, Heimans JJ, Reijneveld JC Synaptic vesicle protein 2A predicts response to levetiracetam in glioma patients. Neurology 2011, 77:532-539.
21. Rogawski MA Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics 2009, 6:344-351.
22. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008, 7:1091-1098.
23. Clusmann H, Schramm J, Kral T, et al. Prognostic factors and outcome after different types of resection for temporal lobe epilepsy. J Neurosurg 2002, 97:1131-1141.
24. Englot DJ, Berger MS, Barbaro NM, Chang EF Predictors of seizure freedom after resection of supratentorial low-grade gliomas. J Neurosurg 2011, 115:240-244.
25. Luyken C, Blümcke I, Fimmers R, et al. The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia 2003, 44:822-830.
26. Chang EF, Potts MB, Keles GE, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 2008, 108:227-235.
27. Sherman JH, Moldovan K, Yeoh HK, et al. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg 2011, 114:1617-1621.
28. Krüger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010, 363:1801-1811.
29. Rosati A, Marconi S, Pollo B, et al. Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. J Neurooncol 2009, 93:319-324.
30. Patt S, Labrakakis C, Bernstein M, et al. Neuron-like physiological properties of cells from human oligodendroglial tumors. Neuroscience 1996, 71:601-611.
31. Aronica E, Boer K, Becker A, et al. Gene expression profile analysis of epilepsy-associated gangliogliomas. Neuroscience 2008, 151:272-292.
32. Conti L, Palma E, Roseti C, et al. Anomalous levels of Cl(-) transporters cause a decrease of GABAergic inhibition in human peritumoral epileptic cortex. Epilepsia 2011, 52:1635-1644.
33. Vezzani A, French J, Bartfai T, Baram TZ The role of inflammation in epilepsy. Nat Rev Neurol 2011, 7:31-40.
34. Liimatainen S, Lehtimäki K, Raitala A, et al. Increased indoleamine 2,3-dioxygenase (IDO) activity in idiopathic generalized epilepsy. Epilepsy Res 2011, 94:206-212.
35. Opitz CA, Litzenburger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011, 478:197-203.
36. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 2004, 45:737-744.
37. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 2005, 4:1912-1922.
38. Ecke I, Petry F, Rosenberger A, et al. Antitumor effects of a combined 5-aza-2-deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res 2009, 69:887-895.
39. Oi S, Natsume A, Ito M, et al. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2-deoxycytidine in glioma cells. J Neurooncol 2009, 92:15-22.
40. Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol 2010, 12:328-340.
41. Ständer M, Dichgans J, Weller M Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells. J Neurooncol 1998, 37:191-198.
42. Lane AA, Chabner BA Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27:5459-5468.
43. Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M Nitrosourea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 2001, 12:217-219.
44. Weller M, Gorlia T, Cairncross JG, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011, 77:1156-1164.
45. Ward MM, Barbaro NM, Laxer KD, Rampil IJ Preoperative valproate administration does not increase blood loss during temporal lobectomy. Epilepsia 1996, 37:98-101.
46. Anderson GD, Lin YX, Berge C, Ojemann GA Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg 1997, 87:25-26.
47. Maschio M, Dinapoli L, Sperati F, Fabi A, Pace A, Vidiri A, Muti P Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life. J Neurooncol 2012, 106:651-656.
48. Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, Konduri SD Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neurooncol 2010, 12:917-927.
49. Weller M, Stupp R, Reifenberger G, Brandes AA, Van den Bent MJ, Wick W, Hegi ME MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat Rev Neurol 2010, 6:39-51.
50. Jaeckle KA, Ballman K, Furth A, Buckner JC Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 2009, 73:1207-1213.
51. Rossetti AO, Stupp R Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 2010, 74:13-29.
52. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
53. Gilbert MR, Wang M, Aldape KD, et al. RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). Proc Am Soc Clin Oncol 2011, 29(suppl). 2006 (abstr).
54. Tsai HC, Wei KC, Tsai CN, et al. Effect of valproic acid on the outcome of glioblastoma multiforme. Br J Neurosurg 2012, 26:347-354.
55. Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W P450 enzyme inducing and nonenzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 2005, 72:255-260.
56. Munster P, Marchion D, Bicaku E, et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 2009, 15:2488-2496.
57. Rocca A, Minucci S, Tosti G, et al. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 2009, 100:28-36.
58. Silva C, Chung FS Pregnancy and cancer. Adv Exp Med Bio 2012, 732:89-102.
59. Kaplan PW Reproductive health effects and teratogenicity of antiepileptic drugs. Neurology 2004, 63:S13-S23.
60. Jetter GM, Cavazos JE Epilepsy in the elderly. Semin Neurol 2008, 28:336-341.
61. Elger CE, Schmidt D Modern management of epilepsy: a practical approach. Epilepsy Behav 2008, 12:501-539.